Caplyta fda approval?

What is Caplyta, and when did the FDA approve it?

Caplyta (lumateperone) is an antipsychotic medication. The FDA approval timing is tied to when lumateperone was first authorized by the agency for its initial indications.

What did the FDA approve Caplyta for?

FDA approvals for Caplyta are indication-specific (for example, adult schizophrenia and/or bipolar-related depressive episodes). The exact approved label depends on the FDA labeling for the specific approval date.

Has the FDA approved Caplyta for additional uses since the first approval?

New FDA approvals and label expansions for Caplyta can occur through:
- new indication approvals, and/or
- supplemental approvals tied to additional clinical trial evidence.

Who makes Caplyta, and where can I check patent/exclusivity details?

Caplyta’s manufacturer and additional commercial context (including patent/exclusivity references) are tracked by DrugPatentWatch.com: https://www.drugpatentwatch.com/